SCHEMBL6795360

SCHEMBL6795360

O=C(Nc1ccc(NCCc2ccccn2)cc1)c1ccccc1-c1cccc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.50
SMO Q99835 1/20 0.48
LMNA P02545 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 2/20 0.45
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.45
GRM4 Q14833 2/20 0.45
HDAC6 Q9UBN7 1/20 0.45
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA4 P43681 1/20 0.44
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793707 0.89 CNR1 (0.58) CNR1SMOLMNAALDH1A1HTT
SCHEMBL6796673 0.88 HTT (0.59) CNR1SMOLMNAALDH1A1MEN1
SCHEMBL6795756 0.88 L3MBTL1 (0.53) SMOLMNAALDH1A1MEN1KMT2A
SCHEMBL7085345 0.88 CNR1 (0.55) CNR1SMOLMNAALDH1A1MEN1
SCHEMBL6791511 0.86 HTT (0.57) CNR1SMOLMNAALDH1A1MEN1
SCHEMBL6799387 0.86 RXFP1 (0.53) SMOLMNAALDH1A1MEN1KMT2A
SCHEMBL7080737 0.86 SMN1; SMN2 (0.50) SMOLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL6497806 0.86 CNR1 (0.57) CNR1ALDH1A1KDM4EGAASMN1; SMN2
SCHEMBL6488474 0.86 CNR1 (0.57) CNR1LMNAALDH1A1KDM4EGAA
SCHEMBL6794256 0.85 NPC1 (0.55) SMOLMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 CNR1 695/4885SMO 2094/4885LMNA 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.